PCN26 PHARMACOECONOMIC ANALYSIS IN SPAIN OF THERAPY WITH ERLOTINIB, DOCETAXEL, PEMETREXED OR BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE FAILED PREVIOUS CHEMOTHERAPY REGIMENS | Publicación